Q1 2026 net loss $4.1M; cash runway extended; FDA agrees path for tab-cel BLA resubmission

Atara Biotherapeutics, Inc.

2026-Q1 EPS reported -$0.29 revenue$516,000

Net loss $4.1M ($0.29 diluted EPS) vs net income $38.0M ($3.50 diluted) in Q1 2025.
Revenue $0.5M (prior Q1: $98.1M) due to FY2025 one-time tab-cel manufacturing transfer revenue.
Cash $8.4M at Mar 31; plus $4.8M ATM proceeds post-quarter; runway into mid-2027.
FDA agreed single-arm ALLELE study with historical control could support tab-cel BLA resubmission; update expected Q3 2026.
R&D expenses $0.2M (vs $27.4M), G&A $3.6M (vs $11.5M) reflecting cost reductions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atara Biotherapeutics, Inc. reported first quarter 2026 results: revenue $0.5 million, net income net loss of $4.1 million, EPS ($0.29) basic and diluted loss per share.

Period: first quarter 2026
Revenue: $0.5 million
Net income: net loss of $4.1 million
EPS: ($0.29) basic and diluted loss per share
Result: reported results

Exact text from the filing

31, 2025. • Net cash used in operating activities was $3.1 million for the first quarter 2026, as compared to $28.1 million in the same period in 2025. • Total revenues were $0.5 million for the first quarter 2026, as compared to $98.1 million for the same period in 2025. The prior ‐ year period reflects a one ‐ time acceleration of revenue recognized upon the

View on SEC.gov

557 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.